U-VUE Biomarker Datasheet - Bcl-XL
| Target: | Bcl-XL |
| Alternative Name: | Bcl-2-like protein 1 |
| Clone: | 54H6 |
| Isotype: | Rabbit IgG |
| Reactivity: | Human |
| Main cell types: | Epithelial cells |
| Subcellular Location: | Nuclear and cytoplasmic; staining is present on the membrane of the nucleus and mitochondria |
| Positive control: | Endometrium, colon |
A member of the Bcl-2 family of proteins, Bcl-xL is a potent anti-apoptotic protein located in the membrane of mitochondria. Presence of Bcl-xL prevents the mitochondrial membrane from becomming permeable by binding to and blocking the voltage-dependant anion channels (VDAC). This inhibits the release of the cytochrome C1, and prevents initiation of the caspase cascade and downstream apoptotic events. Bcl-xL can also directly bind to cytochrome C1 residues to prevent apoptosis. The overexpression of Bcl-xL can occur in certain cancers where increased expression can block or delay the onset of apoptosis. In certain cancers, Bcl-xL can also induce epithelial-mesenchymal transition and promote tumor angiogenesis.
IHC: Anti-Bcl-XL antibody [54H6] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.
IHC: Anti-Bcl-XL antibody conjugate [54H6] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.
ISP: Anti-Bcl-XL antibody conjugate [54H6] staining normal tonsil FFPE tissue (green). Nuclear counterstain in blue.
References
- Baranski, Zuzanna et al. “Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.” Oncotarget vol. 6,34 (2015): 36113-25. DOI: 10.18632/oncotarget.5333
Verification
Each lot of antibody conjugate reagent is quality control tested on positive control tissue and reviewed by Ultivue’s Pathology and Biomarker Analytics group to ensure appropriate staining patterns and signal intensity.
This U-VUE Antibody Conjugate is for Research Use Only. Not for Diagnostic purposes.
